TxCell resumes Phase IIb trial of Ovasave for Crohn's disease
French biotech TxCell (Euronext Paris: TXCL) has been authorized to restart its Phase IIb trial of OvaSave for refractory Crohn’s disease.
The CATS29 trial has been amended after some internal changes at TxCell and the termination of its OvaSave collaboration with Trizell Holding, an affiliate member of the Dr Frederik Paulsen Foundation, in December of last year.
At that point TxCell reacquired full rights to market the drug, and announced its intention to omit the original dose exploring arms in the trial and relaunch the study early this year with MaSTherCell, a contract manufacturing organization (CMO).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze